Navigation Links
Sirius Genomics Announces Issuance of U.S. Patent
Date:10/26/2010

Sirius Genomics Announces Issuance of U.S. Patent


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Medical Pharmaceuticals Click to view news release full screen  

Sirius Genomics Announces Issuance of U.S. Patent

 

VANCOUVER, Oct. 26 /PRNewswire/ - Sirius Genomics, a developer of companion diagnostics, announced today that U.S. Patent # 7,820,376 entitled "Protein C Polymorphisms" has been issued by the United States Patent and Trademark Office. The patent relates to a novel use of a Single Nucleotide Polymorphism (SNP) located in the Protein C gene.

"The patent covers methods of predicting outcome or prognosis in sepsis, and other related conditions, by determining a subject's genotype at the SNP. This patent issuance further strengthens Sirius' patent portfolio and position as a developer of companion diagnostics," stated Dr. Jennifer Kaufman-Shaw, Vice President, Intellectual Property at Sirius Genomics.

"Sirius Genomics' steadily expanding patent estate stems from discoveries made from the Company's focused approach in the identification and validation of genetic markers linked to drug response. Our focus is on improving outcomes for patients treated with various classes of drugs used in the acute care setting," stated Chris Wagner, President and CEO of Sirius Genomics.

Sirius' intellectual property portfolio includes patent families related to several therapies available and under development for sepsis and other acute conditions.  About Sirius Genomics: www.siriusgenomics.com
Sirius Genomics develops companion diagnostics (CDx) that are closely tied to therapeutic decisions, leading to better patient outcomes through personalized medicine. Sirius generates value by improving the safety and effectiveness of pharmaceutical compounds. The Company correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable CDx products that enable better drug treatment. The Company's first product is a genetic predictor of response to treatment for sepsis, a severe blood infection. Learn more at href="http://www.siriusgenomics.com/">www.siriusgenomics.com.

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.



'/>"/>
SOURCE Sirius Genomics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sirius Genomics Announces New Collaboration with UK Critical Care Genomics Group
2. Sirius Genomics to Present at Invest Northwest Conference
3. Sirius Genomics Announces 2009 Board of Directors
4. Dr. Robert Lanza is Featured Guest on Deepak Chopras SIRIUS XM Stars Radio Show
5. Sirius Genomics Announces Change in Leadership
6. Learn Proven Practices to Measure, Align and Transform at SiriusDecisions Sales and Marketing Summit 2010
7. Industry Leaders from Blue Coat, Oracle, Polycom, Siemens and Taleo Headline SiriusDecisions Sales and Marketing Summit 2010
8. Sirius Genomics Announces Appointment of Senior Director of Business Development
9. Rosetta Genomics Announces Conference Call and Webcast of Second Quarter Financial Results
10. DOE JGI Director Eddy Rubin highlights the genomics of plant-based biofuels in the journal Nature
11. Rosetta Genomics Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Research and Markets has announced the addition of ... to their offering. ... , This report describes ... such as proteomics and metabolomics. Molecular diagnostics technologies are used for ... biomarker. Currently the most important applications of biomarkers are ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... resume cervical and lumbar disc production, company President, Jake Lubinski will be traveling ... implanting the AxioMed disc in Cologne and Karlsruhe to discuss the benefits of ...
(Date:12/5/2016)... , Dec. 5, 2016  Renova™ Therapeutics, ... congestive heart failure and other chronic diseases, announced ... the company as Chief Financial Officer (CFO), effective ... with 20 years of experience in financial management ... biotech and software companies. Most recently, Ms. Bovenizer ...
(Date:12/5/2016)... GRAND RAPIDS, Mich. , Dec. 5, 2016 NxGen MDx ... "By bringing the test in house, we,ve been able to improve ... costs down for patients," says Alan Mack , CEO of NxGen ... , , ... increase in test volume has led to more job opportunities at the ...
Breaking Biology Technology:
(Date:12/6/2016)... , Dec. 6, 2016 Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... announced today a five (5) year funding commitment ... to expand the rehabilitation and reentry support to ... History Established in 2004, the Prison Entrepreneurship Program ...
(Date:11/30/2016)... 30, 2016  higi SH llc (higi) announced ... targeting national brands, industry thought-leaders and celebrity influencers ... audiences for taking steps to live healthier, more ... 2012, higi has built the largest self-screening health ... million people who have conducted over 185 million ...
(Date:11/24/2016)... Cercacor today introduced Ember TM Sport ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion ... in approximately 30 seconds. Smaller than a smartphone, using ... to key data about their bodies to help monitor ... Hemoglobin carries oxygen to muscles. When hemoglobin ...
Breaking Biology News(10 mins):